Chappell, L. C., Cluver, C. A., Kingdom, J. & Tong, S. Pre-eclampsia. Lancet 398, 341–354 (2021).
Chaiworapongsa, T., Chaemsaithong, P., Korzeniewski, S. J., Yeo, L. & Romero, R. Pre-eclampsia part 2: prediction, prevention and management. Nat. Rev. Nephrol. 10, 531–540 (2014).
Tong, S. et al. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am. J. Obstet. Gynecol. 226, S1157–S1170 (2022).
Paidas, M. J. et al. Prospective, randomized, double-blind, placebo-controlled evaluation of the pharmacokinetics, safety and efficacy of recombinant antithrombin versus placebo in preterm preeclampsia. Am. J. Obstet. Gynecol. 223, 739.e1–739.e13 (2020).
Ahmed, A. et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG 127, 478–488 (2020).
Cluver, C. A. et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. Am. J. Obstet. Gynecol. 219, 388.e1–388.e17 (2018).
Poston, L. et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 367, 1145–1154 (2006).
Redman, C. W. & Sargent, I. L. Latest advances in understanding preeclampsia. Science 308, 1592–1594 (2005).
Maynard, S. E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).
Binder, N. K. et al. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia. Pregnancy Hypertens. 22, 86–92 (2020).
Li, Z. et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686–692 (2007).
Turanov, A. A. et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. https://doi.org/10.1038/nbt.4297 (2018).
Li, F. et al. Nicotinamide benefits both mothers and pups in two contrasting mouse models of preeclampsia. Proc. Natl Acad. Sci. USA 113, 13450–13455 (2016).
Thadhani, R. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124, 940–950 (2011).
Swingle, K. L. et al. Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia. Nature 637, 412–421 (2025).
Thadhani, R., Cerdeira, A. S. & Karumanchi, S. A. Translation of mechanistic advances in preeclampsia to the clinic: long and winding road. FASEB J. 38, e23441 (2024).
Bergmann, A. et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14, 1857–1867 (2010).
Makris, A. et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension 67, 1263–1272 (2016).
Thadhani, R. et al. Removal of soluble Fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27, 903–913 (2016).
Hershcovici, T., Schechner, V., Orlin, J., Harell, D. & Beigel, Y. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis. J. Clin. Apher. 19, 90–97 (2004).
Datta-Mannan, A. & Wroblewski, V. J. Application of FcRn binding assays to guide mAb development. Drug Metab. Dispos. 42, 1867–1872 (2014).
Jefferis, R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526, 159–166 (2012).
Mimura, Y. et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 37, 697–706 (2000).
Makris, A. et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71, 977–984 (2007).
Baltajian, K. et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am. J. Obstet. Gynecol. 215, 89.e1–89.e10 (2016).
Fein, K. C., Arral, M. L., Kim, J. S., Newby, A. N. & Whitehead, K. A. Placental drug transport and fetal exposure during pregnancy is determined by drug molecular size, chemistry, and conformation. J. Control. Release 361, 29–39 (2023).
Teruel, J. L., Lasuncion, M. A., Navarro, J. F., Carrero, P. & Ortuno, J. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. Metabolism 44, 929–933 (1995).
Kroon, A. A., Swinkels, D. W., van Dongen, P. W. & Stalenhoef, A. F. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. Metabolism 43, 1164–1170 (1994).
Klingel, R., Gohlen, B., Schwarting, A., Himmelsbach, F. & Straube, R. Differential indication of lipoprotein apheresis during pregnancy. Ther. Apher. Dial. 7, 359–364 (2003).
Eichbaum, Q. et al. Apheresis in developing countries around the world. J. Clin. Apher. 30, 238–246 (2015).
Mullard, A. Extracellular targeted protein degrader removes antibodies in first test in humans. Nat. Rev. Drug Discov. 23, 483–486 (2024).
Yonekura Collier, A. R. et al. Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertens. Pregnancy 38, 193–199 (2019).
Khankin, E. V., Mandala, M., Colton, I., Karumanchi, S. A. & Osol, G. Hemodynamic, vascular, and reproductive impact of FMS-like tyrosine kinase 1 (FLT1) blockade on the uteroplacental circulation during normal mouse pregnancy. Biol. Reprod. 86, 57 (2012).
Levine, R. J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683 (2004).
Yuan, H. T., Haig, D. & Karumanchi, S. A.Angiogenic factors in the pathogenesis of preeclampsia. Curr. Top. Dev. Biol. 71, 297–312 (2005).
Saad, A. F. et al. Reference range determination for the sFlt-1/PlGF ratio in a diverse cohort of pregnant women in the United States. J. Appl. Lab. Med. 10, 937–948 (2025).
Verlohren, S. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 202, 161.e1–161.e11 (2010).
Tita, A. T. et al. Treatment for mild chronic hypertension during pregnancy. N. Engl. J. Med. 386, 1781–1792 (2022).
Magee, L. A. et al. Less-tight versus tight control of hypertension in pregnancy. N. Engl. J. Med. 372, 407–417 (2015).
Thadhani, R. et al. Circulating angiogenic factor levels in hypertensive disorders of pregnancy. NEJM Evid. 1, EVIDoa2200161 (2022).
Rana, S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125, 911–919 (2012).
Nakamura, N. et al. Mortality and neurological outcomes in extremely and very preterm infants born to mothers with hypertensive disorders of pregnancy. Sci. Rep. 11, 1729 (2021).
Morgan, A. S., Mendonca, M., Thiele, N. & David, A. L. Management and outcomes of extreme preterm birth. BMJ 376, e055924 (2022).
Biwer, L. A. et al. Smooth muscle mineralocorticoid receptor promotes hypertension after preeclampsia. Circ. Res. 132, 674−689 (2023).
Chaiworapongsa, T., Chaemsaithong, P., Yeo, L. & Romero, R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat. Rev. Nephrol. 10, 466–480 (2014).
Koll, R. A. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins. Ther. Apher. 2, 147–152 (1998).
